AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05027880 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-based single-session growth mindset intervention for adolescent anxiety
Description: This proposed study uses a four-arm, parallel group, cluster randomized controlled trial design to evaluate the efficacy of SIGMA compared to a web-based growth mindset SSI (SSI-GP) and an active web-based control programme. The concurrent parallel group structure assures that the different groups take part in their respective intervention at the same time.
Study NCT05027880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based single-session growth mindset intervention for adolescent anxiety
Description: This proposed study uses a four-arm, parallel group, cluster randomized controlled trial design to evaluate the efficacy of SIGMA compared to a web-based growth mindset SSI (SSI-GP) and an active web-based control programme. The concurrent parallel group structure assures that the different groups take part in their respective intervention at the same time.
Study NCT05131789 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dementia case management information system
Description: The investigators will develop an information system based on the data collected in our previous research, the content and method of dementia case management which will be established by the Delphi method, and then the dementia case management information system will be constructed accordingly.
Study NCT06062953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 3-9 mg flexible dosing before bed time
Study NCT06062953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: 50-150 mg flexible dosing before bed time
Study NCT06062953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1-3 capsules flexible dosing before bed time
Study NCT05753319 — intervention group
Intervention type: OTHER
Intervention: Physiotherapy in the emergency department after a fall
Description: Realization of a physiotherapy assessment.
Study NCT04826419 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ozone therapy
Description: The treatment session of oxygen-ozone was 80 mg/mL ozone (total volume: 60-100 mL) in a special bag using the ozone generator device (Humazon Promedic, German) five times a week for the first week.The treatment session of oxygen-ozone was 40 mg/mL ozone (total volume: 60-100 mL) in a special bag using the ozone generator device (Humazon Promedic, German) twice a week after first week.
Study NCT05132088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide 50 mg
Description: Participants will have semaglutide for 68 weeks and will have 1 tablet every morning.~Dose gradually increased to 50 mg.
Study NCT05132088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (semaglutide)
Description: Participants will have placebo tablets for 68 weeks and will have 1 tablet every morning.
Study NCT04633213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM9036 0.25% Ophthalmic Solution
Description: Ophthalmic Solution
Study NCT04633213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ophthalmic Solution
Study NCT05166720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NIDCAP care
Description: NIDCAP care was performed according to the best evidence of NIDCAP
Study NCT04314570 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saphenous Nerve Block with Ropivacaine Treatment
Description: Regional Anesthesia nerve blocks have become standard practice for several orthopedic surgeries for post-operative pain management, however concerns for compartment syndrome have prevented nerve blocks to become common practice for tibial plateau open reduction internal fixation pain management. Interestingly, saphenous nerve blocks do not cover the sciatic nerve, allowing for pain management while reducing concerns that it may possibly mask compartment syndrome. Patients will receive ropivacaine through the catheter from the start of the nerve block.
Study NCT04314570 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Saphenous Nerve Block with Saline Control
Description: Regional Anesthesia nerve blocks have become standard practice for several orthopedic surgeries for post-operative pain management, however concerns for compartment syndrome have prevented nerve blocks to become common practice for tibial plateau open reduction internal fixation pain management. Interestingly, saphenous nerve blocks do not cover the sciatic nerve, allowing for pain management while reducing concerns that it may possibly mask compartment syndrome. Patients will receive a loading dose of Normal Saline through the catheter. After one hour, the patient will receive their Ropivacaine infusions as per standard protocol.
Study NCT06263517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clodronate
Description: For Arm 1, patients will be treated with intra articular clodronate 2 mg/2 ml from Baseline to Week 3
Study NCT06263517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clodronate
Description: For Arm 2, patients will be treated with intra articular clodronate 5 mg/2 ml from Baseline to Week 3
Study NCT06263517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clodronate
Description: For Arm 3, patients will be treated with intra articular clodronate 10 mg/2 ml from Baseline to Week 3
Study NCT06263517 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For Arm 4, patients will be treated with Placebo 2 ml from Baseline to Week 3
Study NCT06209047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bronchoscopic airway clearance followed by local instillation of gentamicin and dexamethasone
Description: bronchoscopic airway clearance followed by local instillation of gentamicin and dexamethasone
Study NCT05691166 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity progressive resistance training
Description: Supervised high-intensity progressive resistance training twice per week for 12 months
Study NCT05691166 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General practitioner care
Description: Referred to general practitioner (GP) for further follow-up. The GPs will be informed about participants sarcopenia status with results from assessments of muscle strength, muscle mass, and physical performance. The management of the sarcopenia is at the GPs own discretion.
Study NCT05180955 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Digital drainage system
Description: In the intervention group; chest tube removal will be determined by air flow criteria as indicated by the digital drainage system data, the tube will not be clamped.
Study NCT05180955 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Digital drainage system + clamping trial
Description: In the control group removal will be determined by the same criteria of the digital drainage system but before removal, a chest tube clamping test will be performed.
Study NCT04728555 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Game about radiotherapy
Description: A digital pedagogical game about radiotherapy
Study NCT04504149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Readiness for Improvement through Motivation, Engagement, and Decision-making for PTSD
Description: A primary care-based shared decision making intervention
Study NCT04565899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice facilitation implementation intervention
Description: 6 months during which practice facilitation is implemented to support the primary care clinic in improving routine, population-based screening, assessment, treatment, and follow-up for unhealthy alcohol use and AUDs.
Study NCT04585620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Onabotulinum Toxin A
Description: Series of subcutaneous injections
Study NCT04585620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Series of subcutaneous injections
Study NCT04982172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab (Inflectra® \[Pfizer\]), dosage determined using model-informed precision dosing, intravenously administered
Study NCT04982172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Infliximab, dosage following a dose de-escalation algorithm at the physician's discretion, intravenously administered
Study NCT05572385 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CIAT + Conventional neurorehabilitative therapy
Description: CIAT = Constrained induced aphasia therapy
Study NCT06479330 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Milk Chocolate
Description: Acute intake
Study NCT06479330 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Milk Chocolate
Description: Acute intake
Study NCT05556265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Specified dose on specified days
Study NCT05556265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Deucravacitinib
Description: Specified dose on specified days
Study NCT05556265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study NCT05556265 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study NCT05096572 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIM Stimulation
Description: Subjects will receive stimulation at VIM site only based on best settings ascertained during monopolar review.
Study NCT05096572 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSA Stimulation
Description: Subjects will receive stimulation at PSA site only based on best settings ascertained during monopolar review.
Study NCT05096572 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIM+PSA Stimulation
Description: Subjects will receive stimulation at VIM+PSA based on best settings ascertained during monopolar review.
Study NCT05057572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: - Arm A will receive carvedilol plus standard medical therpy,Carvedilol: will be started with initial dose of 3.125 mg BD then After 3 days, increase the dose to 6.25 mg BD, Maximum dose would be 12.5 mg BD, the same shall be switch to Maximum tollrated dose if SBP>90, HR >55.
Study NCT05057572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: * Arm B will receive standard medical therapy.SMT (as described) that is Grade II ascites - Lasilactone (20/50) OD then Change after 1 week as per response, monitor diuretic intolerance.~* Grade III ascites will undergo large volume paracentesis, lasilactone (20/50) OD Both groups will receive albumin as indicated (LT references as per protocol will be send for eligible patients)
Study NCT05057572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: * Arm B will receive standard medical therapy.SMT (as described) that is Grade II ascites - Lasilactone (20/50) OD then Change after 1 week as per response, monitor diuretic intolerance.~* Grade III ascites will undergo large volume paracentesis, lasilactone (20/50) OD Both groups will receive albumin as indicated (LT references as per protocol will be send for eligible patients)
Study NCT05313802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.
Study NCT05989776 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Informational brochure for patients and brief training for oncologists
Description: For this randomized, stepped wedge trial, the investigators planned a mixed intervention that targets both health professionals and patients. This intervention will be carried out in its entirety thanks to the working groups made up of health professionals and expert patients that took place before the randomized trial. The intervention for health professionals consists of awareness training. They will be trained (or made aware) at different times, defined by randomization. The intervention for patients consists of a pictorial information brochure and tabular patient decision aid given by trained health professionals.
Study NCT05833828 — intervention group
Intervention type: PROCEDURE
Intervention: on-pump surgery
Description: the surgery will be performed on-pump
Study NCT05833828 — intervention group
Intervention type: PROCEDURE
Intervention: off-pump surgery
Description: the surgery will be performed off-pump
Study NCT06533631 — intervention group
Intervention type: DEVICE
Intervention: Portable low-field MRI (pMRI)
Description: Participants will receive a pMRI during the study visit.
Study NCT06533631 — intervention group
Intervention type: DEVICE
Intervention: 3T MRI
Description: Gold standard MRI for WMH. Participants will receive a 3T MRI during the study visit.
Study NCT06081959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: IV infusion on day 1 and Day 15 of each 28 day cycle
Study NCT06081959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: 1.4 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle
Study NCT06081959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000-1250 mg/m2, po, bid, from day 1 to Day 15 of each 21 day cycle
Study NCT06081959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m2, IV infusion on day 1 and Day 8 of each 21day cycle
Study NCT06081959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: 25 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle
Study NCT05375084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBP-398 with nivolumab
Description: BBP-398 administered orally once a day (QD); nivolumab administered intravenously every 4 weeks (Q4wks)
Study NCT05366010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oscillation and Lung Expansion (OLE) therapy
Description: Respiratory airway clearance intervention including continuous high-frequency oscillation and continuous positive expiratory pressure
Study NCT05610800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide 2 milligram (mg) Injection
Description: Exenatide will be purchased commercially as Bydureon for subcutaneous (SC) injection and administered at a dose of 2 mg once a week for a total of 14 weeks. Each single-dose, dual-chamber pen contains 0.65 mg of diluent and 2 mg of exenatide, which remains isolated until mixed.
Study NCT05610800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile saline (0.9%) will serve as the placebo for exenatide. The placebo will be administered 2 mg subcutaneously using insulin syringes.
Study NCT05610800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: Nicotine patches will be purchased commercially and dispensed during clinic visits for one week of use.~Participants who smoke >10 cigarettes/day will receive 21 mg patches for the first 12 weeks, 14 mg patches for week 13, and 7 mg patches for week 14.~Participants who smoke 5-10 cigarettes per day will receive 14 mg patches for the first 12 weeks and 7 mg patches for weeks 13 and 14.
Study NCT05610800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine patch
Description: Nicotine patches will be purchased commercially and dispensed during clinic visits for one week of use.~Participants who smoke >10 cigarettes/day will receive 21 mg patches for the first 12 weeks, 14 mg patches for week 13, and 7 mg patches for week 14.~Participants who smoke 5-10 cigarettes per day will receive 14 mg patches for the first 12 weeks and 7 mg patches for weeks 13 and 14.
Study NCT05610800 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Counseling
Description: Participants will receive brief individual behavioral smoking cessation counseling that consist of weekly in-person sessions and 2 brief (10-15 min) supportive phone calls (once pre-quit and again 3-days post-quit), spanning the 14-week active treatment phase. Counseling will be provided by master's level clinicians who will receive at least 8 hours of initial training.
Study NCT05610800 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Smoking Cessation Counseling
Description: Participants will receive brief individual behavioral smoking cessation counseling that consist of weekly in-person sessions and 2 brief (10-15 min) supportive phone calls (once pre-quit and again 3-days post-quit), spanning the 14-week active treatment phase. Counseling will be provided by master's level clinicians who will receive at least 8 hours of initial training.
Study NCT05717803 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Segmentectomy
Description: The lungs are divided into multiple lobes. A segmentectomy involves the removal of part of one of the lobes of the lung to entirely remove a cancerous tumor. segmentectomy can preserve more normal functional lung tissues.
Study NCT05467670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: A type of immunotherapy that stimulates the body's immune system to fight cancer cells by targeting and blocking PD-1 proteins on the surface of certain immune T-cells, thus triggering the T-cells to find and kill cancer cells.
Study NCT05467670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALX148
Description: A fusion protein comprised of a high affinity CD47 blocker linked to an inactive immunoglobulin Fc region, enhancing innate and adaptive immune responses against cancer.
Study NCT05467670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: An anthracycline that slows/stops the growth of cancer cells by blocking an enzyme called topo isomerase 2, used as second line non-platinum chemotherapy in patients with platinum-resistant ovarian cancer.
Study NCT05104424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart
Description: intranasal rapid insulin 40 I.U as 0.1 ml as 2 puff at each nostril once weekly for 8 weeks zinc 50 mg orally daily Gabapentin 300 mg once daily for 1 month small ice cube at mouth before meals thrice daily
Study NCT05104424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin aspart
Description: intranasal rapid insulin 40 I.U as 0.1 ml as 2 puff at each nostril once weekly for 8 weeks zinc 50 mg orally daily Gabapentin 300 mg once daily for 1 month small ice cube at mouth before meals thrice daily
Study NCT04261127 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic diagnosis (PMDA panel)
Description: Blood samples for DNA study
Study NCT04261127 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Use of RADIAL algorithm
Description: RADIAL card filling (contains clinical and biological data)
Study NCT06435806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Illustration design
Description: We will test 10 binary design variants for medical illustrations (for example, with and without cut-away, with and without text labels, etc). Specific variants to be identified during first task of project.
Study NCT05996497 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: behavioral measures
Description: behavioral measures
Study NCT05996497 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electrophysiological measures
Description: Electrophysiological measures
Study NCT05996497 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Training 1
Description: Training 1
Study NCT05996497 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Training 2
Description: Training 2
Study NCT06065709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness breath awareness meditation
Description: Mindfulness breath awareness meditation
Study NCT05298293 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ONCOLAXY Follow-up
Description: The operation of Oncolaxy© is based on the principle of e-PRO (electronic patient reported outcome) which is able to assess the symptoms declared by patients treated for cancer, to detect an evolution, a recurrence or the toxicity of a therapy. Alerts are sent to the healthcare team if the algorithm detects suspicious symptoms or worsening of these symptoms.~Oncolaxy© records symptoms using an electronic questionnaire that allows them to be graded. Questionnaires are sent out on a regular basis. The algorithm analyzes the responses and processes them taking into account the score of the response and its evolution over time. The combination of the results makes it possible to send information to the healthcare teams in charge of the patient that will alert them, enlighten them and help them guide their decisions which remain under their sole control. The summary of the results can be viewed at any time on a dashboard.
Study NCT05654298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Description: Sumatriptan 100 mg
Study NCT05654298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Description: Ubrogepant 100 mg
Study NCT05903040 — intervention group
Intervention type: DRUG
Intervention: Lasmiditan
Description: Patients using Lasmiditan 50-100-200 mg oral tablet to treat acute migraine attacks
Study NCT06176053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Homebased stretching exercise and app supervision
Description: The intervention group will perform a self-administered, home-based stretching program (a total of 6 minutes per day) and maintain their daily activities as identified at baseline. Exercises are to be performed daily for six weeks. Adherence will be supported, and weekly contact with each participant will be maintained via a mHealth application.